HomeHealth CareDrugs

Drugs

Health Care

Atara Bounces Back with FDA

Howard Fine -
Health Care

FDA Again Rejects Atara

Howard Fine -
Health Care

Biotech Giant Amgen Will Expand Its R&D

Howard Fine -
Health Care

NeOnc Sees Share Price Fall Since Going Public

Mark R. Madler -
Health Care

Atara Biotherapeutics Sees Its Share Price Fall

Mark R. Madler -
Health Care

Amgen Plans To Expand N.C. Campus

Howard Fine -
Health Care

Arcutis Wants to Be A Go-To Treatment

Howard Fine -
Drugs

Amgen Drug Gets Second FDA Nod

Antonio Pequeño IV -
Drugs

AskGene Lands $20 Million in Series A Round

Antonio Pequeño -
Drugs

$7.1 Billion Tax Issue Eclipses Amgen’s Quarterly Performance

Joel Russell -
Drugs

Fujifilm Completes Acquisition of Atara Biotherapeutics Facility

Antonio Pequeño IV -
Drugs

Capsida Biotherapeutics Appoints Chief Operating Officer

Antonio Pequeño IV -
Drugs

Amgen Issues ‘Green Bond’

Antonio Pequeño IV -
Drugs

Amgen Quarterly Report, $6 Billion Buyback Pushes Shares Higher

Antonio Pequeño IV -
Drugs

Amgen Forms Collaboration for Hard-to-Treat Diseases

Antonio Pequeño IV -
Drugs

Simulations Plus to Modify Software Through Funded Partnership

Antonio Pequeño IV -
Drugs

Amgen Enters Research Collaboration With Arrakis

Antonio Pequeño IV -
Drugs

Acelyrin Appoints Chief Operating Officer

Antonio Pequeño IV -
Drugs

Amgen and BioLabs LA Award Second Golden Ticket

Antonio Pequeño IV -
Drugs

Amgen Lung Cancer Treatment Approved by European Commission

Antonio Pequeño IV -
Drugs

Arcutis Biotherapeutics Obtains $225 Million in Debt Financing

Antonio Pequeño IV -
Drugs

Amgen’s Otezla Receives Expanded FDA Approval for Plaque Psoriasis

Antonio Pequeño IV -
Drugs

Amgen, AstraZeneca Asthma Drug Approved by FDA

Antonio Pequeño IV -
Drugs

Simulations Plus Donates $25,000 for Medicine Distribution

staff-author -
Sign Up for Daily E-News Updates
Join Our Membership
Latest Articles